COVID-19 and acute lymphoblastic leukemias of children and adolescents: First recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children and adolescents (SFCE).
Adolescent
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Antiviral Agents
/ pharmacokinetics
COVID-19
COVID-19 Testing
Child
Clinical Laboratory Techniques
Combined Modality Therapy
Comorbidity
Coronavirus Infections
/ diagnosis
Disease Management
Down Syndrome
/ epidemiology
Drug Interactions
Febrile Neutropenia
/ chemically induced
Female
Granulocyte Colony-Stimulating Factor
/ therapeutic use
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Immunocompromised Host
Male
Pandemics
/ prevention & control
Pneumonia, Viral
/ diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
Recurrence
Remission Induction
Risk
Risk Assessment
Salvage Therapy
Symptom Assessment
Acute lymphoblastic leukemia-children-adolescents
COVID-19
SARS-CoV-2
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
21
04
2020
revised:
24
04
2020
accepted:
24
04
2020
pubmed:
11
5
2020
medline:
20
6
2020
entrez:
11
5
2020
Statut:
ppublish
Résumé
Since the emergence of the SARS-CoV-2 infection, many recommendations have been made. However, the very nature of acute lymphoblastic leukemias and their treatment in children and adolescents led the Leukemia Committee of the French Society for the fight against cancers and leukemias in children and adolescents (SFCE) to propose more specific recommendations, even if data for this population are still scarce. They may have to evolve according to the rapid evolution of knowledge on COVID-19.
Identifiants
pubmed: 32387061
pii: S0007-4551(20)30201-0
doi: 10.1016/j.bulcan.2020.04.003
pmc: PMC7190519
pii:
doi:
Substances chimiques
Antiviral Agents
0
Granulocyte Colony-Stimulating Factor
143011-72-7
Types de publication
Practice Guideline
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
629-632Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.
Références
N Engl J Med. 2020 Apr 23;382(17):1663-1665
pubmed: 32187458
Eur J Cancer. 2020 Jun;132:11-16
pubmed: 32305831
Bone Marrow Transplant. 2020 Oct;55(10):1900-1905
pubmed: 32313181
Pediatr Blood Cancer. 2020 Jul;67(7):e28392
pubmed: 32383827